Patents by Inventor Van Ma
Van Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12083121Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: January 19, 2022Date of Patent: September 10, 2024Assignee: Amgen Inc.Inventors: John Gordon Allen, Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Jennifer Rebecca Allen, Margaret Chu-Moyer, Albert Amegadzie, Ning Chen, Clifford Goodman, Jonathan D. Low, Vu Van Ma, Ana Elena Minatti, Nobuko Nishimura, Alexander J. Pickrell, Hui-Ling Wang, Youngsook Shin, Aaron C. Siegmund, Kevin C. Yang, Nuria A. Tamayo, Mary Walton, Qiufen Xue
-
Publication number: 20240059703Abstract: Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.Type: ApplicationFiled: October 19, 2021Publication date: February 22, 2024Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, JOSEPHINE ESHON, DAVID HUANG, MATTHEW R. KALLER, HEEJUN LEE, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M MEDINA, ALEXANDER J. PICKRELL, JOHN C. STELLWAGEN, ZHEN SUN, NURIA A. TAMAYO, WENHAN ZHANG, KAI ZHU
-
Publication number: 20240050430Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 23, 2023Publication date: February 15, 2024Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
-
Publication number: 20230406860Abstract: The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.Type: ApplicationFiled: October 26, 2021Publication date: December 21, 2023Inventors: BRIAN ALAN LANMAN, ABHISEK BANERJEE, MARGARET CHU-MOYER, DONGCHENG DAI, MATTHEW R. KALLER, PATRICIA LOPEZ, VU VAN MA, FRANCESCO MANONI, JOSE M. MEDINA, ALEXANDER J. PICKRELL, NURIA A. TAMAYO, KAI ZHU
-
Patent number: 11766436Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: June 30, 2021Date of Patent: September 26, 2023Assignee: Amgen Inc.Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
-
Publication number: 20230159510Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.Type: ApplicationFiled: February 11, 2021Publication date: May 25, 2023Applicant: AMGEN INC.Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
-
Publication number: 20220395504Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 30, 2021Publication date: December 15, 2022Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
-
Publication number: 20220175782Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: January 19, 2022Publication date: June 9, 2022Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
-
Patent number: 11285156Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: June 11, 2019Date of Patent: March 29, 2022Assignee: AMGEN INC.Inventors: John Gordon Allen, Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Jennifer Rebecca Allen, Margaret Chu-Moyer, Albert Amegadzie, Ning Chen, Clifford Goodman, Jonathan D. Low, Vu Van Ma, Ana Elena Minatti, Nobuko Nishimura, Alexander J. Pickrell, Hui-Ling Wang, Youngsook Shin, Aaron C. Siegmund, Kevin C. Yang, Nuria A. Tamayo, Mary Walton, Qiufen Xue
-
Patent number: 11279712Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: GrantFiled: August 27, 2018Date of Patent: March 22, 2022Assignee: AMGEN INC.Inventors: Sean P. Brown, Yunxiao Li, Paul E. Harrington, Brian Alan Lanman, Jonathan D. Low, Ana Elena Minatti, Vu Van Ma, Kexue Li
-
Patent number: 11090304Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: May 3, 2019Date of Patent: August 17, 2021Assignee: Amgen Inc.Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
-
Patent number: 11053226Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: GrantFiled: November 18, 2019Date of Patent: July 6, 2021Assignee: AMGEN INC.Inventors: Youngsook Shin, Victor J. Cee, Christopher M. Tegley, Brian Alan Lanman, Ryan Paul Wurz, Kevin C. Yang, Vu Van Ma, Daniel Erlanson, Joon Won Jeong, Raymond V. Fucini, Jeffrey Iwig
-
Publication number: 20210171529Abstract: The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.Type: ApplicationFiled: November 24, 2020Publication date: June 10, 2021Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, Ning CHEN, Clifford GOODMAN, Giulia LATTANZI, Iain LINGARD, Qingyian LIU, Jonathan D. LOW, Vu Van MA, Ana E. MINATTI, Alfonso POZZAN, Corey REEVES, Aaron C. SIEGMUND, Sabrina TASSINI, Federica TONELLI, Mary WALTON
-
Publication number: 20200247821Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.Type: ApplicationFiled: August 27, 2018Publication date: August 6, 2020Applicant: AMGEN INC.Inventors: Sean P. BROWN, Yunxiao LI, Paul E. HARRINGTON, Brian Alan LANMAN, Jonathan D. LOW, Ana Elena MINATTI, Vu Van MA, Kexue LI
-
Publication number: 20200165231Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: November 18, 2019Publication date: May 28, 2020Inventors: Youngsook SHIN, Victor J. CEE, Christopher M. TEGLEY, Brian Alan LANMAN, Ryan Paul WURZ, Kevin C. YANG, Vu Van MA, Daniel ERLANSON, Joon Won JEONG, Raymond V. FUCINI, Jeffrey IWIG
-
Publication number: 20190374542Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: June 11, 2019Publication date: December 12, 2019Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon Booker, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
-
Publication number: 20190343838Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.Type: ApplicationFiled: May 3, 2019Publication date: November 14, 2019Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
-
Publication number: 20170267673Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.Type: ApplicationFiled: November 17, 2016Publication date: September 21, 2017Applicant: AMGEN INC.Inventors: Jennifer R. ALLEN, Albert AMEGADZIE, Matthew P. BOURBEAU, James A. BROWN, Jian J. CHEN, Yuan CHENG, Michael J. FROHN, Angel GUZMAN-PEREZ, Paul E. HARRINGTON, Longbin LIU, Qingyian LIU, Jonathan D. LOW, Vu Van MA, James R. MANNING, Ana Elena MINATTI, Thomas T. NGUYEN, Nobuko NISHIMURA, Mark H. NORMAN, Liping H. PETTUS, Alexander J. PICKRELL, Wenyuan QIAN, Shannon RUMFELT, Robert M. RZASA, Aaron C. SIEGMUND, Markian M. STEC, Ryan D. WHITE, Qiufen XUE
-
Patent number: 9611261Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.Type: GrantFiled: November 4, 2015Date of Patent: April 4, 2017Assignee: Amgen Inc.Inventors: Ana Elena Minatti, Jonathan D. Low, Jennifer R. Allen, Albert Amegadzie, James Brown, Michael J. Frohn, Angel Guzman-Perez, Paul E. Harrington, Patricia Lopez, Vu Van Ma, Nobuko Nishimura, Wenyuan Qian, Shannon Rumfelt, Robert M. Rzasa, Kelvin Sham, Adrian L. Smith, Ryan White, Qiufen Xue
-
Patent number: 9550762Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.Type: GrantFiled: August 5, 2015Date of Patent: January 24, 2017Assignee: Amgen, Inc.Inventors: Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, James A. Brown, Jian J. Chen, Yuan Cheng, Michael J. Frohn, Angel Guzman-Perez, Paul E. Harrington, Longbin Liu, Qingyian Liu, Jonathan D. Low, Vu Van Ma, James Manning, Ana Elena Minatti, Thomas T. Nguyen, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Alexander J. Pickrell, Wenyuan Qian, Shannon Rumfelt, Robert M. Rzasa, Aaron C. Siegmund, Markian M. Stec, Ryan D. White, Qiufen Xue